FindTrial
Sign In

To study the effect of intervention drug, Tab. Drospirenone as compared to control, Tab. Dienogest on Endometriosis Associated Pain

To study the effect of Drospirenone as compared to Dienogest on Endometriosis Associated Pain: A Randomised Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113587
Enrollment
70
Registered
2026-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N809- Endometriosis, unspecified

Interventions

Intervention1: Tab Drospirenone: Tablet Drospirenone to be given per oral 4 mg once daily for 24 days followed by 4 days of no drug and then restart again for 24 days. This schedule to be followed for

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women aged 18 to 35 years, Presenting with endometriosis associated pain, Not desiring pregnancy, Willingness to use hormonal therapy

Exclusion criteria

Exclusion criteria: Prior hormonal therapy in the last 3 months Undiagnosed genital bleeding Significant renal impairment for Drospirenone

Design outcomes

Primary

MeasureTime frame
Reduction in Pain Timepoint: 0, 3, 6 and 9 months—

Secondary

MeasureTime frame
1. Quality of life score 2. Changes in Ultrasonographic findings in terms of reduced endometrioma size and volumes 3. Changes in Ultrasonographic findings in terms of reduced endometrial thickness 4. Days of unscheduled bleedingTimepoint: 0, 3, 6 and 9 months—

Countries

India

Contacts

Public ContactDr Vishwa Soni

AIIMS, New Delhi

garimakachhawa2012@gmail.com9868246702

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026